MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318192 | Name: Mequitazine
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mequitazine is a potent histamine H1 antagonist or antihistamine. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. Mequitazine provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.

Chemical Structure

Mequitazine
Mequitazine
CAS#29216-28-2

Theoretical Analysis

MedKoo Cat#: 318192

Name: Mequitazine

CAS#: 29216-28-2

Chemical Formula: C20H22N2S

Exact Mass: 322.1504

Molecular Weight: 322.47

Elemental Analysis: C, 74.49; H, 6.88; N, 8.69; S, 9.94

Price and Availability

Size Price Availability Quantity
25mg USD 150.00 Ready to ship
50mg USD 250.00 Ready to ship
100mg USD 450.00 Ready to ship
200mg USD 750.00 Ready to ship
500mg USD 1,150.00 Ready to ship
1g USD 1,850.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Mequitazine; Primalan; Mircol; Metaplexan; Virginan; Instotal; Quitadrill
IUPAC/Chemical Name
10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine
InChi Key
HOKDBMAJZXIPGC-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2
SMILES Code
C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934305000
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#A23M04B25
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Mequitazine is a potent, and long-acting histamine H1 antagonist.
In vitro activity:
TBD
In vivo activity:
Mequitazine, 10-(3-quinuclidinylmethyl) phenothiazine, inhibited contractile responses to KCl, phenylephrine (PE), 5-hydroxytryptamine (5-HT), and Ca2+ in rat aorta. Mequitazine potentiated the relaxation to nitroglycerin (NTG) and isoproterenol. These results suggests that mequitazine may inhibit voltage-operated Ca2+ channels (VOC) and increases the level of cyclic AMP. Reference: J Cardiovasc Pharmacol. 1994 Apr;23(4):669-73. https://pubmed.ncbi.nlm.nih.gov/7516021/
Solvent mg/mL mM
Solubility
DMSO 16.1 49.87
Ethanol 31.0 96.13
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 322.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Satake N, Zhou Q, Shibata S. Possible mechanisms of vasoinhibitory effects of mequitazine, an antiallergic agent, on the contractions of isolated rat aorta induced by K+, phenylephrine, 5-hydroxytryptamine, and Ca2+. J Cardiovasc Pharmacol. 1994 Apr;23(4):669-73. doi: 10.1097/00005344-199404000-00023. PMID: 7516021. 2. Martinez-Mir I, Estañ L, Rubio E, Morales-Olivas FJ. Antihistaminic and anticholinergic activities of mequitazine in comparison with clemizole. J Pharm Pharmacol. 1988 Sep;40(9):655-6. doi: 10.1111/j.2042-7158.1988.tb05331.x. PMID: 2907038.
In vitro protocol:
TBD
In vivo protocol:
1. Satake N, Zhou Q, Shibata S. Possible mechanisms of vasoinhibitory effects of mequitazine, an antiallergic agent, on the contractions of isolated rat aorta induced by K+, phenylephrine, 5-hydroxytryptamine, and Ca2+. J Cardiovasc Pharmacol. 1994 Apr;23(4):669-73. doi: 10.1097/00005344-199404000-00023. PMID: 7516021. 2. Martinez-Mir I, Estañ L, Rubio E, Morales-Olivas FJ. Antihistaminic and anticholinergic activities of mequitazine in comparison with clemizole. J Pharm Pharmacol. 1988 Sep;40(9):655-6. doi: 10.1111/j.2042-7158.1988.tb05331.x. PMID: 2907038.
1: Ahn SH, Maeng HJ. Quantification of mequitazine in human plasma by gas chromatography- quadrupole mass spectrometry and its application to a human pharmacokinetic study. Biomed Chromatogr. 2016 Apr;30(4):574-8. doi: 10.1002/bmc.3585. Epub 2015 Sep 20. PubMed PMID: 26268745. 2: Leroux S, Larquetoux L, Nicolas M, Doris E. Asymmetric synthesis of (+)-mequitazine from quinine. Org Lett. 2011 Jul 1;13(13):3549-51. doi: 10.1021/ol2012567. Epub 2011 Jun 9. PubMed PMID: 21657243. 3: Gonnot V, Nicolas M, Mioskowski C, Baati R. Expedient synthesis of mequitazine an antihistaminic drug by palladium catalyzed allylic alkylation of sodium phenothiazinate. Chem Pharm Bull (Tokyo). 2009 Nov;57(11):1300-2. PubMed PMID: 19881287. 4: Abdel-Moety EM, Ibrahim MA, Rezk MR. Photodegradation and photostability-indication of mequitazine. Spectrochim Acta A Mol Biomol Spectrosc. 2009 Oct 15;74(3):740-5. doi: 10.1016/j.saa.2009.08.006. Epub 2009 Aug 12. PubMed PMID: 19729339. 5: Kumazawa T, Hasegawa C, Lee XP, Marumo A, Shimmen N, Ishii A, Seno H, Sato K. Pipette tip solid-phase extraction and gas chromatography-mass spectrometry for the determination of mequitazine in human plasma. Talanta. 2006 Sep 15;70(2):474-8. doi: 10.1016/j.talanta.2006.02.059. Epub 2006 May 2. PubMed PMID: 18970795. 6: Martín JP, Martinez HG, Pérez GL, Manzur JN. [Efficiency of mequitazine in the treatment of allergic rhinitis and chronic urticaria in children. A bibliographic systematic review]. Rev Alerg Mex. 2008 Jan-Feb;55(1):3-9. Review. Spanish. PubMed PMID: 18697448. 7: Pérez Martín J. [Symptomatic treatment of allergic rhinitis with mequitazine (Primalan)]. Rev Alerg Mex. 2006 Nov-Dec;53(6):195-200. Spanish. PubMed PMID: 17361752. 8: Theunissen EL, Vermeeren A, Ramaekers JG. Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance. Br J Clin Pharmacol. 2006 Jan;61(1):79-86. PubMed PMID: 16390354; PubMed Central PMCID: PMC1884990. 9: Kwon OS, Kim HJ, Pyo H, Chung SJ, Chung YB. Determination of mequitazine in human plasma by gas-chromatography/mass spectrometry with ion-trap detector and its pharmacokinetics after oral administration to volunteers. Arch Pharm Res. 2005 Oct;28(10):1190-5. PubMed PMID: 16276978. 10: Kakinoki K, Yamane K, Yamamoto M, Teraoka R, Sugimoto I, Matsuda Y. Effect of titanium dioxide on photostability of solid-state mequitazine. Chem Pharm Bull (Tokyo). 2005 Sep;53(9):1092-6. PubMed PMID: 16141574. 11: Theunissen EL, Vermeeren A, van Oers AC, van Maris I, Ramaekers JG. A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo. Clin Exp Allergy. 2004 Feb;34(2):250-8. PubMed PMID: 14987305. 12: Il'ina NI, Latysheva TV, Varfolomeeva MI. [Experience in clinical use of primalan (mequitazine) in allergology]. Ter Arkh. 2003;75(4):58-60. Russian. PubMed PMID: 12793141. 13: El-Ragehy NA, Badawey AM, El Khateeb SZ. Stability indicating methods for assay of mequitazine in presence of its degradate. J Pharm Biomed Anal. 2002 Jun 20;29(1-2):121-37. PubMed PMID: 12062671. 14: Dupin O, Compeyre S, Trinquand C, Persi L, Arnaud B. [Value of the conjunctival provocation test in evaluating the activity of 2 concentrations of anti-allergy eyedrops, mequitazine]. J Fr Ophtalmol. 1998 Jan;21(1):12-8. French. PubMed PMID: 9834894. 15: Tasaka K, Akagi M, Mio M, Izushi K, Aoki I. Anti-platelet activating factor, anti-leukotriene D4 and some other antiallergic activities of mequitazine. Arzneimittelforschung. 1990 Oct;40(10):1092-7. PubMed PMID: 1705425. 16: Beaumont G, Dobbins S, Latta D, McMillin WP. Mequitazine in the treatment of hayfever. Br J Clin Pract. 1990 May;44(5):183-8. PubMed PMID: 1975200. 17: Kosturkov G, Mileva Zh, Racheva R, Boĭkikeva M, Mustakov B. [The first impressions of the therapeutic effect of mequitazine (Primalan) in allergic patients]. Vutr Boles. 1990;29(4):88-92. Bulgarian. PubMed PMID: 1980766. 18: Martinez-Mir I, Estañ L, Rubio E, Morales-Olivas FJ. Antihistaminic and anticholinergic activities of mequitazine in comparison with clemizole. J Pharm Pharmacol. 1988 Sep;40(9):655-6. PubMed PMID: 2907038. 19: Kohno S, Yamamura H, Ohata K, Togawa M, Nagai H, Koda A, Yanagihara Y, Shida T, Yatsuzuka A, Yoshida Y, et al. [Antiallergic effects of mequitazine. 2. In vivo experiments]. Nihon Yakurigaku Zasshi. 1988 Aug;92(2):159-65. Japanese. PubMed PMID: 2906316. 20: Demaubeuge J, Tennstedt D, Broux R. Does mast cell protection plus mediator antagonism surpass the effect of a classic antihistaminic in the treatment of chronic urticaria? A double-blind comparison of oxatomide and mequitazine. Dermatologica. 1982 Jun;164(6):386-94. PubMed PMID: 6126399.